X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EG110A is based on company's unique non-replicative HSV-1 vector platform. It is being evaluated in preclinical studies for the treatment of neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Lead Product(s): EG110A
Therapeutic Area: Urology Product Name: EG110A
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
The funding will be used to advance company's pipeline, culminating in the Investigational New Drug application filing for the first clinical study of its lead product, EG110A which targets the silencing of type-C sensory neuronsm and is being developed in urology indications.
Lead Product(s): EG110A
Therapeutic Area: Urology Product Name: EG110A
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $20.2 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
